Similar Articles |
|
The Motley Fool June 9, 2011 Brian Orelli |
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. |
The Motley Fool March 28, 2008 Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. |
The Motley Fool January 3, 2011 Travis Hoium |
Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning. |
The Motley Fool October 28, 2011 Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. |
The Motley Fool August 11, 2010 Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool April 25, 2008 Brian Lawler |
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. |
The Motley Fool November 6, 2007 Brian Lawler |
No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns? |
The Motley Fool January 24, 2008 Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. |
The Motley Fool January 3, 2011 Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool July 25, 2007 Brian Lawler |
Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report. |
The Motley Fool April 23, 2008 Brian Lawler |
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. |
Chemistry World June 9, 2015 Phillip Broadwith |
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis. |
The Motley Fool March 20, 2009 Brian Orelli |
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. |
The Motley Fool June 13, 2007 Brian Lawler |
Tracking Vertex The pharmaceutical updates investors on the progress of its lead compound. |
The Motley Fool October 31, 2011 Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool July 27, 2011 Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
The Motley Fool January 28, 2008 Brian Lawler |
Vertex Has a Lot to Prove Vertex Pharmaceuticals announces that final results from its upcoming phase 3 trials wouldn't be ready until the middle of 2010, a far cry from the filing in 2008 that Vertex was previously forecasting. |
The Motley Fool December 14, 2006 Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool January 30, 2009 Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool April 1, 2008 Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool September 8, 2010 Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool May 17, 2010 Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool September 6, 2011 Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool March 31, 2011 Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool April 27, 2005 Charly Travers |
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. |
The Motley Fool September 7, 2010 Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool March 30, 2009 Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
The Motley Fool April 25, 2011 Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool October 30, 2006 Brian Lawler |
Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data. |
The Motley Fool November 25, 2011 Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool May 23, 2008 Brian Lawler |
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. |
The Motley Fool July 27, 2011 Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool August 4, 2010 Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool January 19, 2012 Brian Orelli |
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. |
The Motley Fool February 24, 2011 Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
The Motley Fool October 31, 2011 Brian Orelli |
When Getting Beat Down Is No Big Deal Merck is getting smacked down by Vertex Pharmaceuticals in the hepatitis C market, but it has the bulk to take a beating. |
American Journal of Nursing August 2010 Lomas & Fowler |
Parents and Children with Cystic Fibrosis A survey was conducted to estimate how many adult patients with cystic fibrosis who receive care at centers accredited by the Cystic Fibrosis Foundation also have biological children with the disease. |
Pharmaceutical Executive April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool March 17, 2008 Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool December 15, 2011 Luke Timmerman |
Vertex Names Jeff Leiden As New CEO, Staring Down Tough New Competition What does new leadership mean for Vertex's future? |
The Motley Fool September 26, 2008 Brian Lawler |
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages. |
The Motley Fool August 4, 2010 Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool March 27, 2007 |
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. |
The Motley Fool August 29, 2011 Anders Bylund |
Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume. |
The Motley Fool April 6, 2011 Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool August 4, 2008 Brian Lawler |
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline. |
The Motley Fool August 10, 2010 Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Chemistry World July 31, 2012 Andrew Turley |
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January. |
The Motley Fool February 10, 2005 Charly Travers |
Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter. |
The Motley Fool July 29, 2011 Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. |